2023-03-08 16:05:11 ET
A French %Biotech firm saw its shares rally strongly on Wednesday after the company announced that the first patient has been screened in the Company’s VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate Safety Simplicity and Efficacy) Phase 3 clinical trial that will evaluate the modified Viaskin™ Peanut 250 ?g patch (DBV712) in peanut-allergic children ages 4 through 7 years, according to the release.
Shares of %DBVTechnologies () reached up to $1.17/share (+13.25%) at the session high following the announcement. This move is a strong continuation of the success this stock has had over the last month.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of %Immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.